Norethindrone

Reading File

Finding Sources

Searching PubMed

norethindrone pharmacology clinical use

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive information. Here is the full answer:

Norethindrone (Norethisterone)

Classification & Chemistry

Norethindrone (nor-ETH-in-drone) is a synthetic progestin derived from 19-nortestosterone - the same structural backbone as testosterone, with a key modification at the 19 position. Its structural similarity to testosterone gives it some intrinsic androgenic activity, which distinguishes it from progesterone-derived progestins.

Drug class: First-generation progestin (19-nortestosterone derivative)
Related compounds: Norethindrone acetate (ester prodrug), levonorgestrel, norgestimate (all 19-nortestosterone derivatives)

Mechanism of Action

Like all steroid hormones, norethindrone acts via intracellular nuclear receptors. It diffuses across cell membranes, binds progesterone receptors with high affinity, and the activated receptor-hormone complex interacts with nuclear chromatin to regulate gene transcription - producing tissue-specific protein synthesis.

Contraceptive mechanisms specifically:

Inhibits LH secretion by the pituitary - suppresses ovulation
Thickens cervical mucus - makes it impenetrable to sperm
Thins the endometrium - creates an inhospitable environment for implantation
When used in combination with estrogen (which blunts FSH), dual suppression of the hypothalamic-pituitary-gonadal axis provides highly effective contraception

Therapeutic Uses

1. Contraception

Formulation	Role
Progestin-only pill ("mini-pill")	Contains norethindrone alone; administered daily at a low, continuous dose
Combination oral contraceptives (COCs)	Paired with ethinyl estradiol (e.g., Tri-Norinyl)
Hormone therapy with estrogen	Norethindrone acetate + estradiol (Activella oral; CombiPatch transdermal)

The progestin-only "mini-pill" is less effective than combination oral contraceptives and is associated with more irregular menstrual cycles. However, it is the preferred option in:

Breastfeeding women (estrogen reduces milk production; progestins do not)
Women over 35 who smoke (estrogen-containing pills carry higher risk of MI and stroke)
Women with contraindications to estrogen (thromboembolic disease, migraine with aura, etc.)

2. Menopausal Hormone Therapy (HT)

For women with an intact uterus, progestins such as norethindrone are combined with estrogen to protect the endometrium against hyperplasia and carcinoma that would occur with unopposed estrogen.

3. Endometriosis

Norethindrone 5 mg/day is co-packaged with GnRH agonists (e.g., leuprolide) to reduce the hypoestrogenic side effects (bone loss, hot flashes) of GnRH therapy while maintaining suppression of endometriotic lesions.

4. Other Gynecologic Indications

Heavy menstrual bleeding / dysmenorrhea
Management of endometriosis as monotherapy
Infertility management

Pharmacokinetics

Parameter	Detail
Administration	Oral (tablets), transdermal (patch - norethindrone acetate)
First-pass metabolism	Significant for natural progesterone; synthetic progestins like norethindrone are more stable, allowing lower effective oral doses
Half-life	7-30 hours - suitable for once-daily dosing
Metabolism	Hepatic; metabolites excreted in urine
Bioavailability	Higher than natural progesterone because it resists first-pass hepatic degradation

The progestin content of oral contraceptives is often standardized using norethindrone equivalents - a reference scale for comparing progestin potency across different OCP formulations.

Adverse Effects

General progestin adverse effects:

Headache
Depression
Weight gain
Changes in libido
Breakthrough/irregular bleeding (especially in mini-pill users)

Androgenic effects (specific to 19-nortestosterone derivatives like norethindrone): Because of structural similarity to testosterone, norethindrone can cause:

Acne
Hirsutism
Oily skin

Progestins with less androgenic activity (norgestimate, drospirenone) are preferred when acne or hirsutism is a concern.

Serious adverse effects (rare, mostly estrogen-related in combined products):

Venous thromboembolism
Thrombophlebitis
Myocardial infarction
Stroke

Risk of these severe events is highest in women over 35 who smoke. Progestin-only products carry a significantly lower thromboembolic risk compared to estrogen-containing formulations.

Drug Interactions

CYP3A4 inducers (rifampin, carbamazepine, phenytoin) - significantly reduce efficacy of norethindrone-containing oral contraceptives. Use barrier backup or alternative contraception.
Broad-spectrum antibiotics - may reduce enterohepatic recycling of estrogen in combined products, potentially diminishing effectiveness.

Contraindications

Active thromboembolic disease or cerebrovascular disease
Estrogen-dependent neoplasms (relevant for combined products)
Liver disease
Pregnancy
Undiagnosed vaginal bleeding

Norethindrone vs. Norethindrone Acetate

Norethindrone acetate is the acetate ester - it has higher potency (roughly twice the progestin activity) and is used in hormone therapy formulations (e.g., Activella, CombiPatch, Loestrin). The free base norethindrone is used in mini-pills and generic formulations.

Key Clinical Pearls

Norethindrone mini-pill must be taken at the same time every day - its short half-life and cervical mucus mechanism mean even a few hours of delay reduces efficacy significantly.
It is the benchmark reference progestin used to convert and compare the androgenic and progestogenic potency of all other OCP progestins.
Unlike medroxyprogesterone injections, norethindrone pills allow rapid return to fertility after discontinuation.
OCP use (with estrogen) is associated with decreased risk of endometrial and ovarian cancer, despite any small increase in cervical cancer risk (attributed to reduced barrier method use and HPV exposure).

Sources: Lippincott Illustrated Reviews: Pharmacology, pp. 831-852; Textbook of Family Medicine 9e, pp. 631-632; Goodman & Gilman's Pharmacological Basis of Therapeutics.

Norethindrone acetate

Finding Sources

Searching PubMed

"norethindrone acetate" clinical use hormone therapy

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Reading Article

PMID: 40233572

Excellent - I now have rich data. Here is the full answer:

Norethindrone Acetate (NETA)

Classification & Chemistry

Norethindrone acetate (nor-ETH-in-drone ASS-eh-tate) is the C-17 acetate ester of norethindrone, belonging to the 19-nortestosterone class of synthetic progestins. The acetate modification increases lipophilicity and slows hydrolysis, making NETA approximately twice as potent as norethindrone on a per-milligram basis. Like norethindrone, it retains some inherent androgenic activity due to its structural similarity to testosterone.

Also known as: Norethisterone acetate (international nomenclature)
Drug class: Synthetic progestin, 19-nortestosterone derivative
Key distinction from norethindrone: Higher potency, wider therapeutic dose range (0.1 mg in HT to 5 mg in endometriosis)

Available Formulations

Brand Name	Components	Route	Primary Use
Loestrin	NETA + ethinyl estradiol	Oral	Contraception
Activella / generics	NETA 0.5 mg + estradiol 1 mg (or 0.1/0.5 mg)	Oral	Menopausal HT
FemHRT Lo	NETA 0.5 mg + ethinyl estradiol 2.5 mcg	Oral	Menopausal HT
CombiPatch	NETA + estradiol	Transdermal patch	Menopausal HT
Generic	NETA alone (5 mg)	Oral	Endometriosis
Oriahnn	NETA 0.5 mg + estradiol + elagolix	Oral	Uterine fibroids
Myfembree	NETA 0.5 mg + estradiol + relugolix	Oral	Uterine fibroids / endometriosis

Therapeutic Uses

1. Oral Contraception

NETA combined with ethinyl estradiol (e.g., Loestrin) provides effective combination oral contraception. The mechanism is identical to other combination OCs - progestin inhibits LH secretion (preventing ovulation), thickens cervical mucus, and thins the endometrium, while estrogen blunts FSH to suppress follicular development.

2. Menopausal Hormone Therapy

NETA is a widely used progestin component in menopausal HT. In women with an intact uterus, progestin is added to any estrogen regimen to prevent endometrial hyperplasia and carcinoma from unopposed estrogen. NETA is available at low doses (0.1-0.5 mg/day) appropriate for this purpose.

Metabolic considerations in HT (important clinical note):

NETA and medroxyprogesterone acetate blunt the HDL-raising effect of estrogen - a potentially adverse cardiovascular consequence
Micronized progesterone does NOT blunt HDL response, and is metabolically preferable in this regard
At lower doses of estrogen, NETA may have an additive benefit on bone density - a unique advantage over medroxyprogesterone
In breast tissue, progestins (including NETA) may contribute to the increased breast cancer risk seen with combined HT

3. Endometriosis

NETA is a key second-line therapy for endometriosis-associated pain and is equally effective to GnRH analogs:

High-dose monotherapy (5 mg/day):

Induces amenorrhea and decidualization/atrophy of endometriotic lesions
Safe, inexpensive alternative to surgical or GnRH-based approaches
Dose is titrated to achieve amenorrhea, then tapered to control symptoms
A 2025 RCT (Gurbuz et al., Eur J Obstet Gynecol, PMID 40233572) found NETA 5 mg/day vs dienogest 2 mg/day both reduced pain scores to near-zero by 12 months, but NETA achieved significantly greater reduction in endometrioma size (p=0.037) and had a lower dropout rate (23.3% vs 47.5%)

Add-back therapy with GnRH agonists (2.5-5 mg/day):

GnRH agonists cause hypoestrogenic side effects: hot flashes, vaginal dryness, mood changes, and 6-8% trabecular bone loss after 6 months
NETA (alone or with low-dose estrogen) as add-back therapy prevents vasomotor symptoms and bone loss while maintaining suppression of endometriotic lesions
Standard add-back regimens include:
- NETA 5 mg/day alone
- NETA 5 mg + conjugated estrogen 0.625 mg/day
- NETA 5 mg + 17β-estradiol 1 mg/day
Important: progestin-only add-back is less protective for bone than estrogen-progestin combination; combined add-back is effective for up to 2 years

4. Uterine Fibroids (FDA-Approved Combination Therapy)

The FDA has approved two oral GnRH antagonist combination therapies specifically for uterine fibroids, both containing NETA as the add-back progestin:

Elagolix + estradiol 1 mg + NETA 0.5 mg (Oriahnn)
Relugolix + estradiol 1 mg + NETA 0.5 mg (Myfembree)

These regimens reduce fibroid-associated heavy menstrual bleeding while preserving bone density - NETA's role here is primarily endometrial and skeletal protection against the GnRH antagonist's hypoestrogenic state.

5. Other Gynecologic Uses

Dysfunctional uterine bleeding / heavy menstrual bleeding
Dysmenorrhea
Premenstrual syndrome
Secondary amenorrhea

Pharmacokinetics

Parameter	Detail
Absorption	Rapidly absorbed orally; more lipophilic than norethindrone
Conversion	Hydrolyzed to norethindrone (active metabolite) in the GI tract and liver
Half-life	~8-11 hours (similar to norethindrone)
Metabolism	Hepatic; primarily via reduction and conjugation
Excretion	Urine (metabolite conjugates)
Transdermal	Available in CombiPatch - avoids first-pass hepatic effect, potentially less impact on lipids

Adverse Effects

Androgenic effects (shared with all 19-nortestosterone derivatives):

Acne, oily skin, hirsutism
These are more pronounced than with progesterone-derived progestins or newer-generation progestins like norgestimate/drospirenone

General progestin effects:

Breakthrough bleeding / irregular menses (especially early in treatment)
Weight gain
Depression, mood changes
Decreased libido
Headache

Metabolic effects:

Blunts estrogen-induced HDL rise - adverse lipid profile effect (vs. micronized progesterone)
Possible contribution to increased breast cancer risk in long-term combined HT (WHI data)

Bone:

At low HT doses: may provide additive benefit on bone density with lower-dose estrogen
At full GnRH add-back doses: prevents GnRH agonist-induced bone loss when combined with estrogen

Key Differentiators vs. Plain Norethindrone

Feature	Norethindrone	Norethindrone Acetate
Potency	Standard	~2x more potent
Dose range in use	0.35 mg (mini-pill)	0.1 mg (HT) to 5 mg (endometriosis)
Main formulations	Mini-pill, some COCs	HT products (Activella, CombiPatch), Loestrin, endometriosis/fibroid combos
Androgenic activity	Present	Present (similar)
Transdermal form	No	Yes (CombiPatch)
HDL blunting in HT	Yes	Yes

Contraindications

Active or history of thromboembolic disease
Active or history of arterial thromboembolic disease (stroke, MI)
Known or suspected estrogen/progestin-dependent malignancy
Active liver disease
Pregnancy or suspected pregnancy
Undiagnosed abnormal uterine bleeding

Recent Evidence

A 2025 RCT (Gurbuz et al., PMID 40233572) directly compared NETA 5 mg vs dienogest 2 mg for endometriosis pain over 12 months. Both equally eliminated dysmenorrhea (VAS 0.00 at 12 months in both groups), but NETA produced significantly greater endometrioma size reduction and had a notably lower discontinuation rate - suggesting NETA 5 mg/day may be preferred over dienogest for endometriosis management.

Sources: Lippincott Illustrated Reviews: Pharmacology, pp. 831-845; Berek & Novak's Gynecology, pp. 579, 674-675; Harrison's Principles of Internal Medicine 22E, pp. Osteoporosis chapter; Goldman-Cecil Medicine, Uterine Fibroids chapter; Gurbuz et al. 2025, PMID 40233572.

This is a shared conversation. Sign in to Orris to start your own chat.